Ocera Therapeutics has started the second part of a Phase 1/2a clinical trial of OCR-002 (ornithine phenylacetate) tablets as…
Maria Verissimo
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.